Advenchen 
Welcome,         Profile    Billing    Logout  
 5 Products   33 Diseases   5 Products   1369 Trials   5508 News 


«12345678910111213...4748»
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Efficacy and safety of anlotinib combined with sintilizumab in locally advanced or metastatic anaplastic thyroid carcinoma. (Hall A; Poster Bd #: 419) -  Apr 24, 2024 - Abstract #ASCO2024ASCO_3553;    
    This suggests that targeting FGF19 amplifications could be a promising approach for treating advanced ESCC. The combination of anlotinib and sintilizumab demonstrated promising activity and manageable toxicity in patients with locally advanced or metastatic ATC, suggesting its potential as a viable therapeutic option for this patient population.
  • ||||||||||  Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
    Updated results from a phase II study of penpulimab plus anlotinib as first-line therapy in metastatic urothelial cancer (mUC). (Hall A; Poster Bd #: 268) -  Apr 24, 2024 - Abstract #ASCO2024ASCO_1738;    
    Background: Cisplatin-based chemotherapy is the standard-of-care systemic treatment for mUC patients with good physical status and organ function, which has shown a response in more than 40% of patients, with mOS approximately 15 months. Penpulimab plus anlotinib demonstrated promising antitumor activity and manageable safety profile with no new safety signal in mUC.
  • ||||||||||  Focus V (anlotinib) / Advenchen, Sino Biopharm
    Retrospective data, Journal, Real-world evidence, Real-world, Metastases:  Anlotinib for Metastatic Progressed Pheochromocytoma and Paraganglioma: A Retrospective Study of Real-World Data. (Pubmed Central) -  Apr 23, 2024   
    Anlotinib monotherapy or in combination with radionuclide therapies shows promising efficacy and safety for the treatment of LA/M PCC and PGL. Multi-tyrosine kinase inhibitors might represent a novel therapeutic strategy for patients with PPGL; however, large-scale prospective randomized, blinded, controlled clinical research studies are required.
  • ||||||||||  Tyvyt (sintilimab) / Innovent Biologics, Focus V (anlotinib) / Advenchen, Sino Biopharm
    Trial completion, Trial primary completion date, Metastases:  Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC) (clinicaltrials.gov) -  Apr 23, 2024   
    P2,  N=30, Completed, 
    Multi-tyrosine kinase inhibitors might represent a novel therapeutic strategy for patients with PPGL; however, large-scale prospective randomized, blinded, controlled clinical research studies are required. Recruiting --> Completed | Trial primary completion date: Dec 2023 --> Sep 2023
  • ||||||||||  Mekinist (trametinib) / Novartis, BeiGene, Focus V (anlotinib) / Advenchen, Sino Biopharm
    Trial completion, Trial completion date, Trial primary completion date:  Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC Patients (clinicaltrials.gov) -  Apr 22, 2024   
    P1,  N=33, Completed, 
    Not yet recruiting --> Recruiting | Initiation date: Apr 2024 --> Jan 2024 Recruiting --> Completed | Trial completion date: Aug 2023 --> Mar 2024 | Trial primary completion date: Jan 2023 --> Jul 2023
  • ||||||||||  Kaitanni (cadonilimab) / Akesobio, Focus V (anlotinib) / Advenchen, Sino Biopharm
    Trial completion date, Trial primary completion date:  Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer (clinicaltrials.gov) -  Apr 18, 2024   
    P2,  N=35, Recruiting, 
    Patients with clinical stage II/III TNBC were treated with 5 cycles of anlotinib (12 Trial completion date: Mar 2025 --> Feb 2027 | Trial primary completion date: Oct 2024 --> Nov 2025
  • ||||||||||  Opdivo (nivolumab) / BMS, Focus V (anlotinib) / Advenchen, Sino Biopharm
    Trial completion date, Trial primary completion date, Combination therapy:  Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors (clinicaltrials.gov) -  Apr 17, 2024   
    P1/2,  N=56, Active, not recruiting, 
    Trial completion date: Mar 2025 --> Feb 2027 | Trial primary completion date: Oct 2024 --> Nov 2025 Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
  • ||||||||||  Kaitanni (cadonilimab) / Akesobio, Focus V (anlotinib) / Advenchen, Sino Biopharm
    Enrollment open, Trial initiation date, Trial primary completion date, Metastases:  Efficacy and Safety of Cadonilimab Plus Anlotinib in Advanced STS That Failed the Previous First-line Standard Treatment (clinicaltrials.gov) -  Apr 17, 2024   
    P2,  N=27, Recruiting, 
    Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Dec 2023 --> Dec 2024 Not yet recruiting --> Recruiting | Initiation date: Jul 2023 --> Feb 2024 | Trial primary completion date: Feb 2024 --> Aug 2024
  • ||||||||||  Retrospective data, Review, Journal, Metastases:  Anti-angiogenesis agents plus chemoradiotherapy for locally advanced nasopharyngeal cancer: a systematic review and meta-analysis. (Pubmed Central) -  Apr 16, 2024   
    Compared with chemoradiotherapy, anti-angiogenesis agents plus chemoradiotherapy could bring more benefits in terms of short-term efficacy, particularly by notably improving both complete response rate and objective response rate, and overall adverse reactions were acceptable. Anti-angiogenesis agents plus chemoradiotherapy may provide a promising direction for the treatment of locally advanced nasopharyngeal carcinoma.